Phaseline

Targets › IGHMBP2

IGHMBP2 (DNA-binding protein SMUBP-2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Mar 2027.

5' to 3' helicase that unwinds both RNA and DNA duplexes in an ATP-dependent reaction (Probable). Specific to 5'-phosphorylated single-stranded guanine-rich sequences. (UniProt, P38935)

Open in Phaseline: the race on IGHMBP2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vanda PharmaceuticalsVCA-894A
antisense oligonucleotide targeting IGHMBP2
IGHMBP2Phase 1Charcot Marie Tooth Disease (CMT)Mar 2027

Conditions

Charcot Marie Tooth Disease (CMT) (1)

Modalities

small molecule (1)

Companies

Vanda Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.